Organon & Co. (NYSE:OGN) will add disclosures to its proxy after a New Jersey lawsuit sought to block the July 23 shareholder vote on the Sun Pharma merger—denied by Organon—while preparing Q2 2026 Form 10-Q and an 8-K with GAAP and non‑GAAP reconciliations as earnings calls stay suspended.
Previous Week Recap
- Organon Adds Proxy Disclosures: Organon & Co. will add disclosures to its proxy for the Sun Pharma merger after a New Jersey lawsuit challenged the proxy and sought to block the July 23 shareholder vote; Organon denies the claims.
- Organon Q2 2026 Filing: Organon (OGN) will report Q2 2026 results via Form 10-Q and file an 8-K with non‑GAAP measures and GAAP reconciliations; earnings calls are suspended pending Sun Pharma acquisition.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.